Mentice AB
STO:MNTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hootech Inc
SZSE:301026
|
CN |
Mentice AB
Goodwill
Mentice AB
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mentice AB
STO:MNTC
|
Goodwill
kr48.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RaySearch Laboratories AB (publ)
STO:RAY B
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ContextVision AB
OSE:CONTX
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Ortivus AB
STO:ORTI B
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sectra AB
STO:SECT B
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
i
|
iZafe Group AB
STO:IZAFE B
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mentice AB
Glance View
Mentice AB provides software and hardware simulation solutions for endovascular therapies. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2019-06-18. The company provides software and hardware simulation solutions and related services for endovascular therapies. The Company’s solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Company’s solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The firm also covers neurovascular, cardiovascular and peripheral interventions, among others. The company is active globally.
See Also
What is Mentice AB's Goodwill?
Goodwill
48.5m
SEK
Based on the financial report for Sep 30, 2025, Mentice AB's Goodwill amounts to 48.5m SEK.
What is Mentice AB's Goodwill growth rate?
Goodwill CAGR 3Y
-1%
Over the last year, the Goodwill growth was 0%. The average annual Goodwill growth rates for Mentice AB have been -1% over the past three years .
